Fragment virtual screening based on Bayesian categorization for discovering novel VEGFR-2 scaffolds

[1]  Li Di,et al.  Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability , 2010, J. Comput. Aided Mol. Des..

[2]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[3]  I. Akritopoulou‐Zanze,et al.  Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[4]  Ben Shneiderman,et al.  Tree visualization with tree-maps: 2-d space-filling approach , 1992, TOGS.

[5]  Frank Oellien,et al.  Enhanced CACTVS Browser of the Open NCI Database , 2002, J. Chem. Inf. Comput. Sci..

[6]  Sun Choi,et al.  In silico classification of adenosine receptor antagonists using Laplacian-modified naïve Bayesian, support vector machine, and recursive partitioning. , 2010, Journal of molecular graphics & modelling.

[7]  Tao Lu,et al.  Fragment-based strategy for structural optimization in combination with 3D-QSAR , 2013, Journal of Computer-Aided Molecular Design.

[8]  Zhiqiang Bai,et al.  Development and strategies of VEGFR-2/KDR inhibitors. , 2012, Future medicinal chemistry.

[9]  Jian Wang,et al.  Novel Strategy for Three-Dimensional Fragment-Based Lead Discovery , 2011, J. Chem. Inf. Model..

[10]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[11]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[12]  M. Socinski,et al.  Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. , 2011, Cancer treatment reviews.

[13]  Stephen J Boyer,et al.  Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. , 2002, Current topics in medicinal chemistry.

[14]  Darko Butina,et al.  Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets , 1999, J. Chem. Inf. Comput. Sci..

[15]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[16]  Mark McGann,et al.  FRED Pose Prediction and Virtual Screening Accuracy , 2011, J. Chem. Inf. Model..

[17]  Konstantin V Balakin,et al.  VEGF/VEGFR signalling as a target for inhibiting angiogenesis , 2007, Expert opinion on investigational drugs.

[18]  David Kombo,et al.  Comparative Study on the Use of Docking and Bayesian Categorization To Predict Ligand Binding to Nicotinic Acetylcholine Receptors (nAChRs) Subtypes , 2013, J. Chem. Inf. Model..

[19]  Youyong Li,et al.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. , 2012, Molecular pharmaceutics.

[20]  Tao Lu,et al.  An Integrated Virtual Screening Approach for VEGFR-2 Inhibitors , 2013, J. Chem. Inf. Model..

[21]  Nanda Ghoshal,et al.  Combinatorial Library Enumeration and Lead Hopping using Comparative Interaction Fingerprint Analysis and Classical 2D QSAR Methods for Seeking Novel GABAA α3 Modulators , 2009, J. Chem. Inf. Model..

[22]  Haichun Liu,et al.  De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction , 2012, Molecular Diversity.

[23]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[24]  Ruifeng Liu,et al.  QSAR Classification Model for Antibacterial Compounds and Its Use in Virtual Screening , 2012, J. Chem. Inf. Model..

[25]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[26]  Maria Kontoyianni,et al.  Evaluation of docking performance: comparative data on docking algorithms. , 2004, Journal of medicinal chemistry.

[27]  I. D. de Esch,et al.  KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. , 2014, Journal of medicinal chemistry.

[28]  Philip Prathipati,et al.  Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..

[29]  William J. Welsh,et al.  Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery , 2013, Journal of Computer-Aided Molecular Design.

[30]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[31]  S. Davidsen,et al.  1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel. , 2007, Journal of medicinal chemistry.

[32]  Mark Whittaker,et al.  The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..

[33]  Yongbo Hu,et al.  Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy , 2009, J. Chem. Inf. Model..

[34]  M. Stahl,et al.  Chemical Fragment Spaces for de novo Design. , 2007 .

[35]  G. Bemis,et al.  BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. , 2004, Journal of medicinal chemistry.

[36]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[37]  P. Leeson,et al.  Drug discovery: Chemical beauty contest , 2012, Nature.

[38]  A. Voet,et al.  Fragment based drug design: from experimental to computational approaches. , 2012, Current medicinal chemistry.

[39]  Alex M. Clark,et al.  2D Depiction of Fragment Hierarchies , 2009, J. Chem. Inf. Model..

[40]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[41]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[42]  Didier Rognan,et al.  Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..

[43]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[44]  Jian-Ping Zhou,et al.  Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met. , 2011, European journal of medicinal chemistry.

[45]  S. Davidsen,et al.  1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors. , 2006, Bioorganic & Medicinal Chemistry Letters.

[46]  Robert C. Glen,et al.  Winnow based identification of potent hERG inhibitors in silico: comparative assessment on different datasets , 2012, Journal of Cheminformatics.

[47]  Thierry Langer,et al.  The Protein Data Bank (PDB), its related services and software tools as key components for in silico guided drug discovery. , 2008, Journal of medicinal chemistry.

[48]  Xiaoyang Xia,et al.  Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.

[49]  I. Akritopoulou‐Zanze,et al.  Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[50]  Malcolm J. McGregor,et al.  Clustering of Large Databases of Compounds: Using the MDL "Keys" as Structural Descriptors , 1997, J. Chem. Inf. Comput. Sci..

[51]  Qian Li,et al.  Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines , 2012, Journal of Cheminformatics.

[52]  M. Radi,et al.  Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. , 2012, Journal of medicinal chemistry.

[53]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[54]  Tingjun Hou,et al.  Recent development and application of virtual screening in drug discovery: an overview. , 2004, Current pharmaceutical design.

[55]  Sarah R. Langdon,et al.  Scaffold Diversity of Exemplified Medicinal Chemistry Space , 2011, J. Chem. Inf. Model..

[56]  Alain Calvet,et al.  Molecular Property eXplorer: A Novel Approach to Visualizing SAR Using Tree-Maps and Heatmaps , 2005, J. Chem. Inf. Model..

[57]  W. F. Hoffman,et al.  Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding. , 2004, Bioorganic & medicinal chemistry letters.

[58]  Anne Mai Wassermann,et al.  Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes. , 2013, Journal of medicinal chemistry.

[59]  Michael M. Hann,et al.  RECAP — Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry. , 1998 .